Sanofi cholesterol drug touted as potential $3 billion blockbuster - (Yahoo!News via NewsPoints Desk)

  • Analysts suggested that an experimental cholesterol drug being developed by Sanofi and Regeneron named alirocumab could generate more than $3 billion in annual sales, as reported Yahoo!News Wednesday.
  • PCSK9 inhibitors such as alirocumab are considered the potentially greatest advance in the treatment of heart disease since the development of statins such as Lipitor and Zocor two decades ago.
  • "Physician feedback suggests high awareness amongst cardiologists and planned prescribing habits support multi-billion dollar potential for the class," remarked Deutsche Bank analysis, who projected annual sales exceeding $3 billion for the therapy, while BioMedTracker estimated sales of $3.7 billion by 2023 for the drug.
  • Sanofi and Regeneron are battling with Amgen to market the first PCSK9 inhibitor, while Pfizer, Eli Lilly and Roche have competing products at earlier stages of development.
  • Results from an ongoing Phase III trial comparing alirocumab to Merck and Co.'s Zetia could increase Sanofi's confidence in the drug, which could be launched by 2015.
  • Analysts believe that the experimental therapy could have a price of about $15 per day, comparable to the prices of injectable diabetes therapies such as Novo Nordisk's Victoza.

To read more NewsPoints articles, click here.